Over the course of four days, the fourth floor of the Hilton Americas in downtown Houston served as a temporary hub for discussions of human genetics, genomics and all things Mendelian. The Houston medical community was proud to welcome the Human Genome Meeting (HGM), an annual scientific conference organized by the Human Genome Organisation (HUGO). The 2016 meeting marked the first time in decades that HUGO was held in the United States.
Offering a unique interplay of plenary lectures, symposia, workshops, poster presentations and laboratory tours, the 2016 HGM brought together genetic and genomic researchers from all corners of the globe. A unifying theme of translation wove potentially disparate threads together, tackling genomics-driven approaches in the diagnosis, treatment and management of cancer and genetic disease—all while inching toward future strategies and technologies for implementation.
“What we wanted to do with this meeting was to focus it down a proper path a bit more than previous meetings and bring experts from all across the world to bear on this issue of translational genomics,” said Andrew Futreal, Ph.D., professor in the department of genomic medicine at The University of Texas MD Anderson Cancer Center, as well as the chair of HUGO’s local organizing committee. “We wanted to think about it from the aspect of risk all the way through treatment and even novel approaches to understanding genomes. That way, we’ll be able to interpret the coming wave of information that’s being derived from more and more ubiquitous use of genome sequences, allowing for a greater understanding of human health and disease.”
Striving to balance contemporary issues in cancer and genetics with technology, ethics and policy, the conference featured over 40 distinguished speakers from throughout the Texas Medical Center, across the country and beyond—covering topics such as “Interpreting Cancer Genomes,” “Genome Editing” and “Mendelian Genetics”—in addition to 56 oral presentations from submitted abstracts and 60 poster presentations.
The roller-coaster history of genetic medicine is reflected in the evolution of the meeting itself. In 1991, HUGO held its first meeting with a singular purpose in mind: to collaborate on the ambitious goal of mapping the human genome.
“Initially, the goal of HUGO was to coordinate scientific efforts for the mapping and sequencing of the human genome,” said Stylianos E. Antonarakis, M.D., president of HUGO, as well as professor and chairman of genetic medicine at the University of Geneva Medical School. “I remember the meetings that we held at that time were mostly working meetings; there were very few talks. You would come with your lab books that showcased the results of your mapping experiments, and your fellow scientists would do the same. Then we’d put them together and compare them. If they were the same that was great—if not, we’d try to resolve any differences.”
Those targeted ambitions would define the HGM for more than 10 years—when the titular acronym actually stood for “Human Genome Mapping.” Over the years, and spurred by the completion of the Human Genome Project, HUGO was forced to leave the meeting’s origins behind.
“HUGO didn’t have anything left to coordinate afterwards,” Antonarakis said. “That led the organization to concentrate on ethics statements, policy issues and how to best advise different parts of the world on the importance of the genomic variation in phenotypes on disorders and traits. Gradually, the importance of HUGO went from North America and Europe to the parts of the world that were not that developed in genetic services, thinking and research. And that’s where we are today.”
This year’s conference kicked off with a plenary session that showcased both the storied history and daring ambitions of genomic medicine. Entitled, “At 30, Genomics Comes of Age,” and led by Maynard V. Olson, Ph.D., professor of genome sciences and medicine at the University of Washington, the talk called for a serious reevaluation of priorities and processes now that genome sequencing has established a firm foothold in medicine.
“Now is decidedly the time to really think boldly about the policies that we’ll need over the next decades to optimize genomics’ potential to advance progress in medicine,” Olson said. “This is going to be an immensely greater challenge than the one that the Human Genome Project represented. Obviously, it’s greater in scale, but the real key is that we get ahead of the curve of scientific progress.”
The 2016 HGM featured a “Meet the Professors” series, during which attendees—from students and postdocs to young faculty members—had an opportunity to sit down with the speakers themselves. The four-day conference also included a tour of Baylor College of Medicine’s Human Genome Sequencing Center. For Antonarakis, the opportunity for a younger generation of researchers to visit real-life sequencing center—rather than experience a series of slides on a screen—is a testament to the value HGM provides its attendees.
“We’d like HUGO to continue to have more focused meetings in the future,” Antonarakis said. “Next year’s meeting will be on how genomics informs treatment. In genetics, diagnosis runs much faster than treatment, so we want to emphasize treating disorders with different approaches, from drugs to interventions and changes in lifestyle. We’d like to learn from the experts and each other while we explore these possibilities.”
Earn #CME while discussing novel and multidisciplinary approaches for treating genitourinary cancers on Nov. 1-2. Experts include @aapariciomd, @SurenaMatinMD, @EfstathiouEleni, @nnavai, @ChadTangMD and @cgwoodMD.Learn more: https://t.co/iklv6ISIxh #endcancer
#VHAiEx is coming and you can watch every story, every innovation, every discovery LIVE! Join us for the kickoff right here on Oct. 22: https://t.co/C7kimBMAhf
Veterans are brewing up beer with pints that give back https://t.co/zyAMdwAUAs via @FoxBusiness
“My sons wouldn’t be here if I didn’t come to MD Anderson,” says #lymphoma survivor Brian Heard: https://t.co/2TMtqzzpkB #lymsm #endcancer https://t.co/0NdB8ZbW47
“Circulating tumor DNA is certainly in newly diagnosed, untreated metastatic patients is a very reliable and accurate, and rapid way to assess the genotyping of the patients,” says our @skopetz of #colorectalcancer treatment: https://t.co/J95RXtY787 #endcancer
#VHADiffusion is #ChangingLivesSavingLives and you can see exactly how live at #VHAiEx with successful innovators from across the country presenting their work. https://t.co/crrVTdE42o
Preclinical research helps explain why fatty livers are more susceptible to cancer: https://t.co/pCHsQGgOVD
Dr. Neil Hanchard talks about his work sequencing genomes from countries across Africa. https://t.co/A4hKregVX3 #ASHG19 #genomes
Hear George Springer talk about the team behind the team. We're honored to take care of the @Astros.Let’s knock it out of the park tonight! ⚾ #TakeItBack https://t.co/opulRnD9s6
@lexi_red We'd like to hear more about your experience. Please send your contact information and Memorial Hermann location to email@example.com so we can look into this.
RT @CHI_StLukes: Ready for Game 4 of the #ALCS? Experts from @bcmhouston and Baylor St. Luke’s share health tips to get you through the @as…
RT @bcm_careerdev: Thanks to Dr. Melissa Sistrunk @NLawGlobal for serving as a job shadow host + exposing @bcmhouston students to #IPLaw c…
Memorial Hermann Sports Park, a new sports medicine and human performance facility on the campus of Memorial Hermann Katy Hospital, opened this past weekend. Learn more: https://t.co/HouQEszaCU. #sports #sportsmedicine https://t.co/PFeyxV28wb
CHI St. Luke's Health@CHI_StLukes
Ready for Game 4 of the #ALCS? Experts from @bcmhouston and Baylor St. Luke’s share health tips to get you through the @astros playoff series. #HoustonAstros #TakeItBack @SeragHashem @isulapas @CBallantyneMD https://t.co/jjIXwSMRWO
.@UTHealth welcomes new members to its Development Board: https://t.co/EId51KaDBF #ManyFacesOfUTHealth